secondary progressive multiple sclerosis
Neurology · 2019–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| siponimod Treatment of secondary progressive multiple sclerosis (SPMS), specifically as a 1 mg tablet formulation for patients with certain CYP2C9 genotypes. | Mar 2024 | Recommended with restriction | none received |
| siponimod Treatment of secondary progressive multiple sclerosis (SPMS) in adult patients. | Nov 2019 | Not recommended | 3 individuals MS Australia · MS Research Australia |
Who spoke
MS Australia · MS Research Australia
What the PBS pays
$13M in government benefit over 2024–25, across 5,892 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| siponimod | $12.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.